Diligence memo · auto-generated · as of July 2, 2026
Tempero Bio, Inc.
Tempero Bio, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Tempero Bio, Inc. operates in Biotechnology, based in OAKLAND.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Tempero Bio, Inc. has raised $77M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $77M on 2024-10-30.
Most recent recorded round closed around 2024-10-30.
Valuation (modeled)modeled
Provath models Tempero Bio, Inc. at approximately $605M (range $238M–$879M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.22× the median modeled value of Series C Biotechnology companies in 2022–2024 (111 peers) — value vs value, same stage and era. Within the normal band (122% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 20 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 87% of Biotechnology peers (4293 compared).
Modeled value ranks above 85% of those peers.
Closest niche peers: Dianthus Therapeutics, Inc., Satellite Biosciences, Inc., Deepcell, Inc., Ventus Therapeutics U.S., Inc., Morphic Holding, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.